memantine teva 20 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - memantini hydrochloridum - tabletki powlekane - 20 mg
memantine teva 5 mg; 10 mg; 15 mg; 20 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - memantini hydrochloridum - tabletki powlekane - 5 mg; 10 mg; 15 mg; 20 mg
memantine orion 20 mg tabletki powlekane
orion corporation - memantini hydrochloridum - tabletki powlekane - 20 mg
memantine glenmark 10 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - memantini hydrochloridum - tabletki powlekane - 10 mg
atlantis 12 od
bayer ag_x000d_ kaiser-wilhem-allee, 51 373 , niemcy - mezosulfuron metylowy; jodosulfuron metylosodowy - jodosulfuron metylosodowy - 2 g, _x000d_ mezosulfuron metylowy - 10 g_x000d_ w 1 litrze środka - chwastobójczy
atlantis star
bayer sas_x000d_ 16 rue jaen marie leclair, 69009 lyon, republika francuska - mezosulfuron metylowy; tienkarbazon metylu; jodosulfuron metylosodowy - mezosulfuron metylowy - 45 g, _x000d_ tienkarbazon metylu - 22,5 g, _x000d_ jodosulfuron metylosodowy - 9 g - chwastobójczy
asanti
rudnikagro sp. z o.o._x000d_ ul. pomorska, 70-812 - para-nitrofenolan sodu - 3 g, _x000d_ orto-nitrofenolan sodu - 2 g, _x000d_ 5-nitrogwajakolan sodu - 1 g - regulator wzrostu
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Środki przeciwnowotworowe - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
cometriq
ipsen pharma - cabozantinib - nowotwory tarczycy - Środki przeciwnowotworowe - leczenie dorosłych pacjentów z progresywnym, nieoperacyjnym miejscowo zaawansowanym lub z przerzutami rdzeniastym rakiem tarczycy.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - chłoniak, mantle-cell - Środki przeciwnowotworowe - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).